BioRestorative Therapies Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Public

  • Employees
  • 14

Employees

  • Stock Symbol
  • BRTX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.31
  • (As of Thursday Closing)

BioRestorative Therapies General Information

Description

BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.

Contact Information

Formerly Known As
Stem Cell Assurance
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 40 Marcus Drive
  • Suite One
  • Melville, NY 11747
  • United States
+1 (631)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 40 Marcus Drive
  • Suite One
  • Melville, NY 11747
  • United States
+1 (631)

BioRestorative Therapies Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioRestorative Therapies Stock Performance

As of 19-Nov-2026, BioRestorative Therapies’s stock price is $1.31. Its current market cap is $1.81M with 1.38M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.31 $1.32 $1.28 - $28.20 $1.81M 1.38M 29.8K -$21.40

BioRestorative Therapies Financials Summary

As of 31-Mar-2026, BioRestorative Therapies has a trailing 12-month revenue of $358K.

In Thousands,
USD
TTM 31-Mar-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,994 5,954 (3,136) (3,836)
Revenue 358 360 401 146
EBITDA (10,846) (14,298) (9,406) (10,804)
Net Income (11,057) (14,242) (8,979) (10,418)
Total Assets 4,640 4,080 12,280 12,612
Total Debt 0 0 0 162
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BioRestorative Therapies Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BioRestorative Therapies‘s full profile, request access.

Request a free trial

BioRestorative Therapies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving ad
Biotechnology
Melville, NY
14 As of 2025

Melbourne, Australia
 

Salt Lake City, UT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioRestorative Therapies Competitors (11)

One of BioRestorative Therapies’s 11 competitors is Mesoblast, a Corporation company based in Melbourne, Australia.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mesoblast Corporation Melbourne, Australia
DiscGenics Venture Capital-Backed Salt Lake City, UT
FibroGenesis Formerly Angel backed Houston, TX
Regeneron Pharmaceuticals Formerly VC-backed Tarrytown, NY
Isto Biologics Private Equity-Backed Hopkinton, MA
You’re viewing 5 of 11 competitors. Get the full list »

BioRestorative Therapies Patents

BioRestorative Therapies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020265664-A1 Non-naturally occuring three-dimensional (3d) brown adipose-derived stem cell aggregates, and methods of generating and using the same Active 29-Apr-2019
AU-2020265664-B2 Non-naturally occuring three-dimensional (3d) brown adipose-derived stem cell aggregates, and methods of generating and using the same Active 29-Apr-2019
EP-3962501-A2 Non-naturally occuring three-dimensional (3d) brown adipose-derived stem cell aggregates, and methods of generating and using the same Active 29-Apr-2019
EP-3962501-A4 Non-naturally occuring three-dimensional (3d) brown adipose-derived stem cell aggregates, and methods of generating and using the same Active 29-Apr-2019
EP-3962501-B1 Non-naturally occuring three-dimensional (3d) brown adipose-derived stem cell aggregates, and methods of generating and using the same Active 29-Apr-2019 A61K35/35
To view BioRestorative Therapies’s complete patent history, request access »

BioRestorative Therapies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioRestorative Therapies Acquisitions (1)

BioRestorative Therapies’s most recent deal was a Merger/Acquisition with Traxxec. The deal was made on 17-Apr-2009.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Traxxec 17-Apr-2009 Merger/Acquisition Other Containers and Packaging
To view BioRestorative Therapies’s complete acquisitions history, request access »

BioRestorative Therapies ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

39.39 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view BioRestorative Therapies’s complete esg history, request access »

BioRestorative Therapies FAQs

  • When was BioRestorative Therapies founded?

    BioRestorative Therapies was founded in 1997.

  • Where is BioRestorative Therapies headquartered?

    BioRestorative Therapies is headquartered in Melville, NY.

  • What is the size of BioRestorative Therapies?

    BioRestorative Therapies has 14 total employees.

  • What industry is BioRestorative Therapies in?

    BioRestorative Therapies’s primary industry is Biotechnology.

  • Is BioRestorative Therapies a private or public company?

    BioRestorative Therapies is a Public company.

  • What is BioRestorative Therapies’s stock symbol?

    The ticker symbol for BioRestorative Therapies is BRTX.

  • What is the current stock price of BioRestorative Therapies?

    As of 19-Nov-2026 the stock price of BioRestorative Therapies is $1.31.

  • What is the current market cap of BioRestorative Therapies?

    The current market capitalization of BioRestorative Therapies is $1.81M.

  • What is BioRestorative Therapies’s current revenue?

    The trailing twelve month revenue for BioRestorative Therapies is $358K.

  • Who are BioRestorative Therapies’s competitors?

    Mesoblast, DiscGenics, FibroGenesis, Regeneron Pharmaceuticals, and Isto Biologics are some of the 11 competitors of BioRestorative Therapies.

  • What is BioRestorative Therapies’s annual earnings per share (EPS)?

    BioRestorative Therapies’s EPS for 12 months was -$21.40.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process